Pharma Innovation Is Highest Where It Matters Most, FDA Analysis Shows
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A new system of measuring innovation in new drugs proposed by analysts from FDA’s Office of Planning paints a rational picture of drug development oriented by medical need, with the greatest innovation in serious and life-threatening conditions.